CD7-CART (Institute of Hematology & Blood Diseases Hospital)

This is an autologous CD7-targeted chimeric antigen receptor (CAR) T-cell therapy developed by the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences. The therapy involves genetically modifying a patient's own T-cells to express a CAR that recognizes the CD7 antigen, which is highly expressed in various T-cell malignancies. To overcome the challenge of "fratricide"—where CAR-T cells attack each other due to shared CD7 expression—the cells are typically engineered using gene-editing techniques to eliminate endogenous CD7 expression. It is currently being evaluated in Phase 2 clinical trials for the treatment of relapsed or refractory CD7-positive T-cell lymphoma, often in conjunction with autologous hematopoietic stem cell transplantation (ASCT) to enhance therapeutic efficacy and hematopoietic recovery.

Other names

ASCT+CD7-CARTautologous CD7-targeted CAR-T cell therapy